头颈癌幸存者神经病理性疼痛的患病率及危险因素
该横断面调查采用S-LANSS量表评估头颈癌幸存者神经病理性疼痛(NP)的患病率及危险因素。505例中45%(227/505)报告疼痛,13.7%(69/505)S-LANSS阳性。调整阿片类药物后,族裔/种族、年龄、手术、抑郁和合并症是NP的危险因素。作者认为NP在头颈癌幸存者中仍普遍,强调常规疼痛监测的重要性。
要点
- 头颈癌幸存者中45%(227/505)报告疼痛,13.7%(69/505)S-LANSS阳性提示神经病理性疼痛。
- NP阳性者中重度疼痛比例为23.2%,高于NP阴性者的13.3%(p=0.004)。
- 调整阿片类药物后,族裔/种族、年龄、手术、抑郁和合并症为NP的危险因素。
核心结论
- 神经病理性疼痛在头颈癌幸存者中仍普遍存在,凸显常规疼痛监测的重要性。
研究设计与样本
- 横断面调查,评估头颈癌幸存者神经病理性疼痛的人口学、行为和临床危险因素,共505例。
- 神经病理性疼痛采用自填式利兹神经病理性症状和体征评估疼痛量表(S-LANSS)评估。
主要发现
- 45%(227/505)报告有疼痛,其中13.7%(69/505)S-LANSS阳性。
- 报告疼痛部位位于头部和口腔区域者占46.2%,位于颈部和喉部者占41.5%。
- NP阳性者使用镇痛药物比例为41.2%,NP阴性者为27.4%(p=0.020);NP阳性者使用替代疼痛治疗比例为19.1%,NP阴性者为8.4%(p=0.009)。
- 重度疼痛在NP阳性者中更常见(NP阳性23.2% vs NP阴性13.3%,p=0.004)。
- 调整阿片类药物后,族裔/种族、年龄、手术、抑郁和合并症是NP的危险因素。
临床怎么用
- 作者认为神经病理性疼痛在头颈癌幸存者中仍普遍存在,强调常规疼痛监测的重要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuropathic pain (NP) is a debilitating symptom among head and neck cancer (HNC) survivors although few large studies report its prevalence and associated risk factors. METHODS: A cross-sectional survey assessing demographic, behavioral, and clinical risk factors for NP. NP was assessed using the Self-administered Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS). RESULTS: Forty-five percent (227/505) reported having pain including 13.7% (69/505) who were positive for S-LANSS. Reported pain sites were in the regions of the head and oral cavity (46.2%) and neck and throat (41.5%). Despite a higher self-reported use of analgesic medication (NP+ = 41.2%; NP- = 27.4%; p = 0.020) and alternative pain therapies (NP+ = 19.1%; NP- = 8.4%; p = 0.009), severe pain was more prevalent among those with NP (N+ = 23.2%; NP- = 13.3%; p = 0.004). Adjusted for opioid medications, ethnicity/race, age, surgery, depression, and comorbidities were risk factors for NP. CONCLUSION: NP remains prevalent in HNC survivors highlighting the importance of routine pain surveillance.
引用
- Rojo RD, Ren JL, Lipe DN, et al. Neuropathic pain prevalence and risk factors in head and neck cancer survivors. Head Neck. 2022. PMID: 36129114. doi:10.1002/hed.27199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。